Development of a Novel, Sequentially Active-targeted Drug Delivery Nanoplatform for Breast Cancer Therapy




Satsangi, Arpan

Journal Title

Journal ISSN

Volume Title



Breast cancer is the second most common cause of cancer-related deaths in women. Chemotherapy is an important treatment modality, and paclitaxel (PTX) is often first-line therapy for the metastatic form. Two notable limitations related to PTX-based treatment are PTX's poor hydrophilicity and the systemic toxicity due to its non-specific distribution among tissues.

This work describes an approach to counter both challenges by designing a prodrug-conjugate of PTX with a hydrophilic macromolecule that is coupled through an active-targeting, enzyme-cleavable linker. However, the targeting of a single molecular cue on cancer cells often leads to serious cytotoxic risk to important normal cells with similar molecular expression profiles. Therefore, a multi-core, multi-targeting device for tumor specific delivery of PTX was designed for enhanced cancer cell selectivity and reduced toxic side-effects, while maintaining capabilities to overcome physiological barriers. The prodrug conjugate of PTX constituted the inner core and was encapsulated in an outer liposomal core that targets a cell surface receptor upregulated in cancer cells and is equipped to exploit the EPR effect for passive targeting of tumors.

As compared to unbound PTX, the non-encapsulated prodrug-conjugate demonstrated a higher cytotoxicity specific to cell lines with moderate-to-high cathepsin B activity and demonstrated higher tumor reduction in MDA-MB-231 xenograft models. Similarly, compared to standard single-targeting liposomal PTX, the multi-targeting construct showed better cytotoxicity against cell lines overexpressing both targeted molecular features and had a higher tumor reduction capability in xenografts. Thus, a novel drug delivery platform with great potential impact on cancer treatment has been developed.


This item is available only to currently enrolled UTSA students, faculty or staff. To download, navigate to Log In in the top right-hand corner of this screen, then select Log in with my UTSA ID.


Biocleavable linker, Breast cancer, Dendrosome, Drug delivery, Nanotechnology, Sequential active-targeting



Biomedical Engineering